Skip to content

Intelligent Clinlabomics Research Elites (iCARE) - A clinical research for lung cancer diagnosis and prognosis assessing ( iCARE-lung-01)

Intelligent Clinlabomics Research Elites (iCARE) - A clinical research for lung cancer diagnosis and prognosis assessing ( iCARE-lung-01)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103183
Enrollment
Unknown
Registered
2025-05-26
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

patients with NSCLC:None
patients with benignancy nodules:None

Sponsors

Sichuan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: NSCLC Patients: Patients admitted with pulmonary nodules or masses diagnosed by LDCT. Postoperative pathology confirms NSCLC. Benign Pulmonary Nodule Patients: Patients admitted with pulmonary nodules or masses diagnosed by LDCT. Postoperative pathology confirms a benign lesion. Healthy Individuals: Aged 40-80 years. No pulmonary nodules confirmed by LDCT during routine health check-ups.

Exclusion criteria

Exclusion criteria: NSCLC Patients: Patients without LDCT results. Patients lacking complete clinicopathological diagnosis. Patients whose tumors could not be accurately resected. Patients diagnosed with a non-NSCLC subtype. Patients with non-primary NSCLC. Patients with other malignancies. Patients lost to follow-up. Benign Pulmonary Nodule Patients: Patients without LDCT results. Patients lacking complete clinicopathological diagnosis. Patients whose tumors could not be accurately resected. Patients with other malignancies. Patients lost to follow-up. Healthy Individuals: Individuals without LDCT results. Individuals with other underlying diseases. Individuals with a history of blood donation or transfusion within one month prior to the health check-up. Individuals lost to follow-up.

Design outcomes

Primary

MeasureTime frame
NSCLC Risk Prediction Score;Accuracy of NSCLC Risk Prediction Model;NSCLC Patient Prognostic Risk Score;Accuracy of NSCLC Prognostic Model;

Secondary

MeasureTime frame
Clinlabomics features;Imaging Indicators;Pathological Indicators;NSCLC Incidence Rate;Treatments;Survival Analysis Metrics;Recurrence Status;

Countries

China

Contacts

Public ContactZu Ruiling

Sichuan Cancer Hospital

1217202695@qq.com+86 185 0282 8171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026